AUTHOR=Patton Laura , Monteith Bethany , Heffernan Paul , Herzinger Thomas , Wilson Brooke E. 

TITLE=Hemophagocytic lymphohistiocytosis/cytokine release syndrome secondary to neoadjuvant pembrolizumab for triple-negative breast cancer: a case study

JOURNAL=Frontiers in Oncology

VOLUME=Volume 14 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1394543

DOI=10.3389/fonc.2024.1394543

ISSN=2234-943X

ABSTRACT=As indicaJons for immune checkpoint inhibitors (ICI) for breast cancer conJnue to expand, rare toxiciJes will emerge that require careful consideraJon and mulJdisciplinary management. We report the case of a 40 year old female receiving neoadjuvant pembrolizumab and chemotherapy for locally advanced triple negaJve breast cancer who developed Cytokine Release Syndrome (CRS)/HemophagocyJc LymphohisJocytosis (HLH). CRS/HLH secondary to pembrolizumab are scarcely documented in the literature, and to our knowledge have never been reported in the context of neoadjuvant treatment for breast cancer.